With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--is now no longer listed as being in short supply in the U.S. and the FDA has told anyone distributing copies of the ...